Paul Tudor Jones’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-14,984
| Closed | -$1.1M | – | 4046 |
|
|
2026
Q1 | $1.08M | Buy |
+14,984
| New | +$853K | ﹤0.01% | 2319 |
|
|
2025
Q4 | – | Sell |
-5,435
| Closed | -$309K | – | 3867 |
|
|
2025
Q3 | $309K | Buy |
+5,435
| New | +$180K | ﹤0.01% | 2958 |
|
|
2025
Q2 | – | Sell |
-3,806
| Closed | -$38.8K | – | 3597 |
|
|
2025
Q1 | $38.8K | Hold |
3,806
| – | – | ﹤0.01% | 2965 |
|
|
2024
Q4 | $53.1K | Hold |
3,806
| – | – | ﹤0.01% | 2928 |
|
|
2024
Q3 | $74.2K | Hold |
3,806
| – | – | ﹤0.01% | 2606 |
|
|
2024
Q2 | $70.8K | Hold |
3,806
| – | – | ﹤0.01% | 2216 |
|
|
2024
Q1 | $53.3K | Hold |
3,806
| – | – | ﹤0.01% | 2113 |
|
|
2023
Q4 | $32.3K | Hold |
3,806
| – | – | ﹤0.01% | 2277 |
|
|
2023
Q3 | $34K | Hold |
3,806
| – | – | ﹤0.01% | 2194 |
|
|
2023
Q2 | $32.8K | Hold |
3,806
| – | – | ﹤0.01% | 2336 |
|
|
2023
Q1 | $40K | Sell |
3,806
-13,916
| -79% | -$421K | ﹤0.01% | 2293 |
|
|
2022
Q4 | $601K | Sell |
17,722
-82
| -0.5% | -$3.97K | 0.01% | 1462 |
|
|
2022
Q3 | $855K | Sell |
17,804
-14,449
| -45% | -$860K | 0.02% | 1023 |
|
|
2022
Q2 | $1.84M | Buy |
32,253
+740
| +2% | +$46.7K | 0.05% | 556 |
|
|
2022
Q1 | $2.55M | Buy |
31,513
+22,829
| +263% | +$3.38M | 0.06% | 433 |
|
|
2021
Q4 | $1.76M | Buy |
8,684
+2,210
| +34% | +$479K | 0.03% | 698 |
|
|
2021
Q3 | $1.74M | Sell |
6,474
-5,383
| -45% | -$1.29M | 0.03% | 806 |
|
|
2021
Q2 | $3.05M | Buy |
+11,857
| New | +$3.28M | 0.06% | 396 |
|
|
2021
Q1 | – | Sell |
-1,160
| Closed | -$296K | – | 1762 |
|
|
2020
Q4 | $296K | Sell |
1,160
-5,571
| -83% | -$1.44M | 0.01% | 1127 |
|
|
2020
Q3 | $1.68M | Buy |
6,731
+379
| +6% | +$119K | 0.07% | 364 |
|
|
2020
Q2 | $2.21M | Buy |
6,352
+3,700
| +140% | +$1.15M | 0.11% | 219 |
|
|
2020
Q1 | $710K | Sell |
2,652
-6,652
| -71% | -$2.06M | 0.06% | 358 |
|
|
2019
Q4 | $3.01M | Buy |
9,304
+8,442
| +979% | +$2.45M | 0.14% | 174 |
|
|
2019
Q3 | $236K | Buy |
+862
| New | +$316K | 0.01% | 925 |
|
|
2018
Q4 | – | Sell |
-413
| Closed | -$378K | – | 1170 |
|
|
2018
Q3 | $378K | Sell |
413
-6,858
| -94% | -$5.85M | 0.01% | 772 |
|
|
2018
Q2 | $5.33M | Buy |
+7,271
| New | +$8.38M | 0.19% | 63 |
|
|
2016
Q2 | – | Sell |
-913
| Closed | -$188K | – | 1822 |
|
|
2016
Q1 | $188K | Buy |
+913
| New | +$175K | ﹤0.01% | 1520 |
|
|
2015
Q3 | – | Sell |
-796
| Closed | -$149K | – | 1680 |
|
|
2015
Q2 | $149K | Buy |
+796
| New | +$137K | ﹤0.01% | 1381 |
|
|
2015
Q1 | – | Sell |
-780
| Closed | -$181K | – | 1560 |
|
|
2014
Q4 | $181K | Buy |
+780
| New | +$167K | 0.01% | 1292 |
|
Other funds holding NKTR
TSC
BI
VPC
Paul Tudor Jones's NKTR Position: Q2 2026 in Review
Paul Tudor Jones sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 14,984 shares — an estimated $1.1M sold.
Paul Tudor Jones first reported a position in NKTR in Q4 2014 and held it in 29 quarters. The position peaked at $5.33M in Q2 2018. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.
- Paul Tudor Jones reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
- Paul Tudor Jones sold 14,984 Nektar Therapeutics shares in Q2 2026, an estimated $1.1M.
- Paul Tudor Jones first reported a position in Nektar Therapeutics in Q4 2014 and held it in 29 quarters.
- Paul Tudor Jones's Nektar Therapeutics position peaked at $5.33M in Q2 2018.
- 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.
Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.